Clinical Trials Logo

Clinical Trial Summary

This phase II trial studies how well lenvatinib and everolimus work in treating patients with carcinoid tumors that have spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Lenvatinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To estimate the Response Evaluation Criteria in Solid Tumors (RECIST) (per version 1.1) objective response rate of lenvatinib in combination with everolimus among patients with advanced carcinoid tumors. SECONDARY OBJECTIVES: I. To evaluate the progression free survival duration of lenvatinib in combination with everolimus among patients with advanced carcinoids. II. To evaluate the safety and tolerability of lenvatinib in combination with everolimus among patients with advanced carcinoid tumors. EXPLORATORY OBJECTIVES: I. To determine clinic benefit rate at 6 months (defined as complete response plus partial response plus stable disease) with lenvatinib + everolimus among patients with advanced carcinoid tumors. II. To determine early CgA and neuron-specific enolase (NSE) response rates. OUTLINE: Patients receive lenvatinib orally (PO) daily and everolimus PO daily on days 1-28. Treatments repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03950609
Study type Interventional
Source M.D. Anderson Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date July 30, 2019
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04464122 - Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Active, not recruiting NCT03375320 - Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Phase 3
Active, not recruiting NCT03980925 - Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. Phase 2
Recruiting NCT02402244 - Project: Every Child for Younger Patients With Cancer
Recruiting NCT05113355 - Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm Phase 2
Recruiting NCT05879055 - A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN Phase 2
Terminated NCT03001349 - 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Early Phase 1
Completed NCT02399215 - Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Phase 2
Recruiting NCT05165407 - Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC Phase 2
Recruiting NCT04927611 - Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm
Active, not recruiting NCT01638533 - Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Phase 1
Recruiting NCT02817945 - Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging Early Phase 1
Active, not recruiting NCT04750954 - Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors Phase 1
Active, not recruiting NCT02402920 - Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer Phase 1
Not yet recruiting NCT04931446 - Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis
Recruiting NCT04720391 - Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)
Recruiting NCT03734913 - A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT03511768 - A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms Phase 1/Phase 2
Recruiting NCT06276309 - Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
Recruiting NCT04917484 - Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients Phase 2